Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunostem gene-modified autologous HSPC therapy for recent-onset type 1 diabetes
2025-521304-21-00Phase 2Authorised
- Sponsor
- Altheia Science
- Start
- Mar 2026
- Modality
- Stem Cell Therapies → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Immunostem in diabetes mellitus type 1 (T1D), sponsored by Altheia Science. Primary endpoint: Safety. Planned start Mar 2026; status: authorised.
02
Drugs
Immunostem
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2025-521304-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521304-21-00.